effect of ivermevectin and brimonidine combination in rosacea
Phase 2
Recruiting
- Conditions
- rosacea.rosacea
- Registration Number
- IRCT20161207031288N7
- Lead Sponsor
- Center For Research and Training in skin Diseases and Leprosy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Having rosacea disease
treatment received in last three months
men and women over 18 years
Exclusion Criteria
More than 5 inflammatory acne lesions
Special forms of rosacea in addition to Dermatosis
Seborrheic dermatits
Acute lupus erythematosus
demodicosis
actinic telangiectasia
Hypersensitivity to brimonidine/Ivermectin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of lesions according to and Clinician Erythema Assessment (CEA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: physical exam.
- Secondary Outcome Measures
Name Time Method Severity of lesions according to Patient Self-Assessment (PSA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: Questionnaire.